Expert recommendations on the challenges of hypertension in Asia

International Journal of Clinical Practice

Volumn 62, Issue 9, 2008, Pages 1306-1312

  Chung, N ^a,b   Baek, S ^c   Chen, M F ^d   Liau, C S ^d   Park, C G ^e   Park, J ^f   Saruta, T ^g   Shimamoto, K ^h   Wu, Z ⁱ   Zhu, J ^j   Fujita, T ^k  

^a Yonsei University Health System   (South Korea)

^b Yonsei University   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e Korea University College of Medicine   (South Korea)

^f Sungkyunkwan University   (South Korea)

^g KEIO UNIVERSITY   (Japan)

^h SAPPORO MEDICAL UNIVERSITY   (Japan)

ⁱ CAPITAL MEDICAL UNIVERSITY   (China)

^j FUDAN UNIVERSITY   (China)

^k UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RENIN INHIBITOR;

ASIA; AWARENESS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; EARLY DIAGNOSIS; ECONOMIC DEVELOPMENT; FOOD INTAKE; HEALTH CARE ACCESS; HEALTH CARE INDUSTRY; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HEART REHABILITATION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; MEDICAL EDUCATION; MEDICAL EXPERT; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SOCIAL ASPECT; TREATMENT OUTCOME;

ADULT; ASIA; CLINICAL COMPETENCE; EARLY DIAGNOSIS; EDUCATION, MEDICAL; HEALTH PERSONNEL; HEALTH SERVICES ACCESSIBILITY; HUMANS; HYPERTENSION; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; SOCIOECONOMIC FACTORS;

EID: 49349114370     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01838.x     Document Type: Conference Paper

References (63)

1. Fujita T. Getting patients to goal: optimal targets and therapies. Int J Clin Pract 2006 60 (Suppl. 150 1 2.
2. Kim JS, Jones DW, Kim SJ, Hong YP. Hypertension in Korea: a national survey. Am J Prev Med 1994 10: 200 4.
3. Choi KM, Park HS, Han JH et al. Prevalence of prehypertension and hypertension in a Korean population: Korean National Health and Nutrition Survey 2001. J Hypertens 2006 24: 1515 21.
4. Wu Y. Overweight and obesity in China. BMJ 2006 333: 362 3.
5. Shimamoto T, Iso H, Iida M, Komachi Y. Epidemiology of cerebrovascular disease: stroke epidemic in Japan. J Epidemiol 1996 6 (Suppl. 3 S43 7.
6. Martiniuk AL, Lee CM, Lawes CM et al. Hypertension: its prevalence and population-attributable fraction for mortality from cardiovascular disease in the Asia-Pacific region. J Hypertens 2007 25: 73 9.
7. Wang Y, Mi J, Shan XY, Wang QJ, Ge KY. Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int J Obes (Lond) 2007 31: 177 88.
8. Gu D, Gupta A, Muntner P et al. Prevalence of cardiovascular disease risk factor clustering among the adult population of China: results from the International Collaborative Study of Cardiovascular Disease in Asia (InterAsia). Circulation 2005 112: 658 65.
9. Jee SH, Appel LJ, Suh I, Whelton PK, Kim IS. Prevalence of cardiovascular risk factors in South Korean adults: results from the Korea Medical Insurance Corporation (KMIC) Study. Ann Epidemiol 1998 8: 14 21.
10. Leeder S, Raymond S, Greenberg H, Liu H, Esson K. A Race Against Time: The Challenge of Cardiovascular Disease in Developing Economies. New York: Columbia University, 2004.
11. WHO. World Health Report. Reducing Risks, Promoting Healthy Life. Geneva: World Health Organization, 2002.
12. Yoon SJ, Bae SC, Lee SI et al. Measuring the burden of disease in Korea. J Korean Med Sci 2007 22: 518 23.
13. WHO. Preventing Chronic Diseases: a Vital Investment. Geneva: World Health Organisation, 2005.
14. Korean Institute of Health and Social Affairs. The Third Korea National Health and Nutrition Examination Survey, 2005. Seoul: Ministry of Health and Welfare, 2005.
15. Whelton PK, He J, Muntner P. Prevalence, awareness, treatment and control of hypertension in North America, North Africa and Asia. J Hum Hypertens 2004 18: 545 51.
16. Japanese Society of Hypertension Subcommittee for the Management of Hypertension. Guidelines for the management of hypertension for general practitioners. Hypertens Res 2001 24: 613 34.
17. Saito I, Kawabe H, Tsujioka M, Hirose H, Shibata H. Trends in pharmacologic management of hypertension in Japan one year after the publication of the JSH 2000 guidelines. First Japanese Society of Hypertension. Hypertens Res 2002 25: 175 8.
18. Ikeda N, Hasegawa T, Saito I, Saruta T. Awareness of the Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2000) and compliance to its recommendations: surveys in 2000 and 2004. J Hum Hypertens 2006 20: 263 6.
19. Fujita T, Shimamoto K, Wu Z et al. What are the major challenges in getting patients to the optimal BP goal? Difficulties in educating doctors and patients. Int J Clin Pract 2006 60 (Suppl. 150 20 2.
20. Jiang X, Li W, Ma L, Kong L, Jin S, Liu L. Knowledge on hypertension and the effect of management on hypertension in patients attending hospital clinics [Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi 2002 23: 269 72.
21. Lin T, Chen CH, Chou P. A hypertension control program in Yu-Chi Taiwan: preliminary results. J Formos Med Assoc 1997 96: 613 20.
22. Lim TO, Ngah BA. The Mentakab Hypertension Study project. Part II - Why do hypertensives drop out of treatment? Singap Med J 1991 32: 249 51.
23. Jokisalo E, Kumpusalo E, Enlund H, Takala J. Patients' perceived problems with hypertension and attitudes towards medical treatment. J Hum Hypertens 2001 15: 755 61.
24. Petrella RJ, Campbell NR. Awareness and misconception of hypertension in Canada: results of a national survey. Can J Cardiol 2005 21: 589 93.
25. Berlowitz DR, Ash AS, Hickey EC et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998 339: 1957 63.
26. Asai Y, Heller R, Kajii E. Hypertension control and medication increase in primary care. J Hum Hypertens 2002 16: 313 8.
27. WHO. Adherence to Long-Term Therapies: Evidence for Action. Geneva: World Health Organization, 2003.
28. Kim EY, Han HR, Jeong S et al. Does knowledge matter? Intentional medication nonadherence among middle-aged Korean Americans with high blood pressure. J Cardiovasc Nurs 2007 22: 397 404.
29. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006 296: 2563 71.
30. Fujii J, Seki A. Compliance and compliance-improving strategies in hypertension: the Japanese experience. J Hypertens Suppl 1985 3: S19 22.
31. Bangalore S, Kamalakkannan G, Panjrath G, Messerli FH. Fixed-dose combination improves medication compliance: a meta-analysis [Abstract]. J Clin Hypertens 2006 8 (Suppl. A A72, P-157.
32. Jackson KC, Brixner D, Oderda GM, Oberg B, Sheng X, Keskinaslan A. Compliance and persistence of fixed dose versus free dose combination therapy with valsartan and HCTZ for patients with hypertension [Abstract]. Value Health Suppl 2006 9: A363, PCV85.
33. Li WW, Stewart AL, Stotts N, Froelicher ES. Cultural factors associated with antihypertensive medication adherence in Chinese immigrants. J Cardiovasc Nurs 2006 21: 354 62.
34. Fu D, Fu H, McGowanII P et al. Implementation and quantitative evaluation of chronic disease self-management programme in Shanghai China: randomized controlled trial. Bull World Health Organ 2003 81: 174 82.
35. Lv YY, Li ZG, Wang LH et al. Evaluation on the case management program of hypertension in Zhongguancun community, Beijing [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi 2005 26: 400 3.
36. Leung CM, Ho GK, Foong M, Ho CF, Lee PK, Mak LS. Small-group hypertension health education programme: a process and outcome evaluation. J Adv Nurs 2005 52: 631 9.
37. Miura S, Yamaguchi Y, Urata H et al. Efficacy of a multicomponent program (patient-centered assessment and counseling for exercise plus nutrition [PACE + Japan]) for lifestyle modification in patients with essential hypertension. Hypertens Res 2004 27: 859 64.
38. Jiang X, Sit JW, Wong TK. A nurse-led cardiac rehabilitation programme improves health behaviours and cardiac physiological risk parameters: evidence from Chengdu, China. J Clin Nurs 2007 16: 1886 97.
39. Qureshi NN, Hatcher J, Chaturvedi N, Jafar TH. Effect of general practitioner education on adherence to antihypertensive drugs: cluster randomised controlled trial. BMJ 2007 335: 1030.
40. Yip YB, Wong TK, Chung JW, Ko SK, Sit JW, Chan TM. Cardiovascular disease: application of a composite risk index from the Telehealth System in a district community. Public Health Nurs 2004 21: 524 32.
41. Wang PE, Wang TT, Chiu YH, Yen AM, Chen TH. Evolution of multiple disease screening in Keelung: a model for community involvement in health interventions? J Med Screen 2006 13 (Suppl. 1 S54 8.
42. Lin JW, Chu PL, Liou JM, Hwang JJ. Applying a multiple screening program aided by a guideline-driven computerized decision support system - a pilot experience in Yun-Lin, Taiwan. J Formos Med Assoc 2007 106: 58 68.
43. Huang G, Gu D, Wu X et al. Cost-effectiveness analysis of Beijing Fangshan cardiovascular prevention program in 1992-1997 [in Chinese]. Zhonghua Yu Fang Yi Xue Za Zhi 2000 34: 78 80.
44. Wu XG, Gu DF, Wu YF et al. An evaluation on effectiveness of worksite-based intervention for cardiovascular disease during 1974-1998 in capital iron and steel company of Beijing [in Chinese]. Zhonghua Yu Fang Yi Xue Za Zhi 2003 37: 93 7.
45. Yeh L, Lu FH, Wang CJ. A preliminary study on the health promotion outcomes of high-risk hypertensive freshmen. Kaohsiung J Med Sci 2002 18: 557 65.
46. Wang H. Social change and its potential impacts on Chinese population health. Hygiea Int 2004 1: 109 51.
47. Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA 2004 291: 2616 22.
48. Hagihara A, Murakami M, Chishaki A, Nabeshima F, Nobutomo K. Rate of health insurance reimbursement and adherence to anti-hypertensive treatment among Japanese patients. Health Policy 2001 58: 231 42.
49. Chiang CW, Chen CY, Chiu HF, Wu HL, Yang CY. Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997-2003. Pharmacoepidemiol Drug Saf 2007 16: 412 21.
50. Chou CC, Lee MS, Ke CH, Chung MH. Prescription patterns of hypertension - National Health Insurance in Taiwan. J Chin Med Assoc 2004 67: 123 30.
51. Mori H, Ukai H, Yamamoto H et al. Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006 29: 143 51.
52. Weber MA. The evolution of combination therapy in treating hypertension. J Clin Hypertens (Greenwich) 2007 9 (Suppl. 5 1 4.
53. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003 289: 2560 72.
54. Mancia G, De Backer G, Dominiczak A et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 25: 1105 87.
55. Japanese Society of Hypertension. Guidelines for the management of hypertension (JSH 2004). Hypertens Res 2006 29 (Suppl. S1 105.
56. Mochizuki S, Dahlof B, Shimizu M et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007 369: 1431 9.
57. Fujita T, Wu Z, Park J-B, Chen M-F. Briefings on JHS, CHS, KHS and THS guidelines and their difference from JNC VII and ESC/ESH. Int J Clin Pract 2006 60 (Suppl. 150 3 6.
58. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001 285: 2486 97.
59. International Diabetes Federation. The IDF Consensus Worldwide Definition of the Metabolic Syndrome. http://www.idf.org/webdata/docs/MetS_def_update2006. pdf (accessed July 2007).
60. WHO Consultation. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organization, 1999.
61. Committee to Evaluate Diagnostic Standards for Metabolic Syndrome. Definition and the diagnostic standard for metabolic syndrome. An examination committee for criterion of metabolic syndrome: definition and criteria of metabolic syndrome. Nippon Naika Gakkai Zasshi 2005 94: 794 809.
62. Thomas GN, Ho SY, Janus ED, Lam KS, Hedley AJ, Lam TH. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese population. Diabetes Res Clin Pract 2005 67: 251 7.
63. Ko GT, So WY, Chan NN et al. Prediction of cardiovascular and total mortality in Chinese type 2 diabetic patients by the WHO definition for the metabolic syndrome. Diabetes Obes Metab 2006 8: 94 104.